Alzheimer's & Dementia News and Research

Latest Alzheimer's & Dementia News and Research

BELLUS Health records a net loss of $4,193,000 for first-quarter 2010

BELLUS Health Inc. reported today its financial results for the first quarter ended March 31, 2010.

12 May 2010

Genetic variations do not improve ability to predict risk of AD: Study

Although genome-wide analysis identified two genetic variations associated with Alzheimer disease, these variations did not improve the ability to predict the risk of AD, according to a study in the May 12 issue of JAMA.

12 May 2010

COTI announces favourable independent pre-IND gap analysis report for novel oncology drug candidate

Critical Outcome Technologies Inc. announced today that it received a favourable Pre-Investigational New Drug (pre-IND) gap analysis report from an independent team that reviewed its novel oncology drug candidate COTI-2. This represents an important milestone as the Company draws closer to a Phase 1 clinical trial.

12 May 2010

Academic scientist receives $125,000 from ADDF/LBDA program to study LBD

The Alzheimer's Drug Discovery Foundation and the Lewy Body Dementia Association announced today the recipient of their first partnership research award through the Lewy Body Dementia Biomarker Research Program.

12 May 2010

Neurimmune Therapeutics honored with ZKB TECHNOPARK Pioneer Award

The ZKB TECHNOPARK® Pioneer Award, which has been sponsored by the Zürcher Kantonalbank since 2000, was presented for the 20th time at TECHNOPARK® Zurich. The award is given for technological innovations which - thanks to pioneering entrepreneurial achievements - are about to be launched on the market. This year's award winner is Neurimmune Therapeutics AG, represented by Dr. Jan Grimm, Professor Christoph Hock, Professor Roger Nitsch and Dr. Michael Salzmann.

12 May 2010

Brookdale Senior Living announces sale of 10,000,000 shares by Fortress Investment Group affiliates

Brookdale Senior Living Inc. announced today the sale of an aggregate of 10,000,000 shares of its common stock by certain affiliates of Fortress Investment Group LLC. The Company will not sell any shares in the offering and will not receive any of the proceeds from the offering. Subject to customary conditions, the offering is expected to close on May 17, 2010.

12 May 2010

Study confirms Resveratrol's impact on cognitive processes of the brain

The subject of extensive studies across the world, Resveratrol is proving to be a major talking point in the scientific community. And as evidence comes to light of the continuing beneficial effects of this compound, a further study by the University of Northumbria in the UK has confirmed what many scientists already believe to be the case - that Resveratrol could have a significant impact on the cognitive processes of the human brain.

12 May 2010

FDA approves delivery of Cefepime in B. Braun's DUPLEX System

The U.S. Food and Drug Administration recently approved an application that permits B. Braun Medical Inc. (B. Braun) to deliver FDA-approved 1g and 2g Cefepime for Injection USP and Dextrose Injection USP in B. Braun's DUPLEX® Drug Delivery System.

From B. Braun Melsungen AG 12 May 2010

Phase IIb study of EVP-6124 initiated in patients with Alzheimer's disease

EnVivo Pharmaceuticals today announced the initiation and dosing of patients in a Phase IIb study of its EVP-6124 compound, a selective alpha-7 nicotinic agonist in patients with mild to moderate Alzheimer's disease.

12 May 2010

Amorfix, Epitomics collaborate to develop high-affinity monoclonal antibodies against cancer targets

Amorfix Life Sciences and Epitomics, Inc. announced today that they have entered into an agreement to develop high-affinity monoclonal antibodies against a number of targets for cancer. Amorfix has identified several disease specific epitopes (DSEs) on misfolded proteins with their proprietary ProMIS(TM) computational platform discovery technology, which will be used by Epitomics to generate highly specific monoclonal antibodies (mAbs).

11 May 2010

Transition Therapeutics reports increased revenue in third-quarter 2010

Transition Therapeutics Inc., a product-focused biopharmaceutical company developing therapeutics for disease indications with large markets, today announced its financial results for the quarter ended March 31, 2010.

11 May 2010

ACADIA Pharmaceuticals reports increased revenue in first-quarter 2010

ACADIA Pharmaceuticals Inc., a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today reported its unaudited financial results for the first quarter ended March 31, 2010.

11 May 2010

Patients with semantic dementia have altered sense of flavours

Flavour is literally the spice of life and for many people life without the pleasures of the table would be unthinkable. Yet just this aspect of everyday life is vulnerable in certain degenerative dementias, with patients developing abnormal eating behaviours including changes in food preferences, faddism and pathological sweet tooth.

11 May 2010

A cutting-edge symposium sheds light on the possibilities of molecular neuroimaging

SNM's Molecular Imaging Center of Excellence wrapped up its Molecular Neuroimaging Symposium today in Bethesda, Md., at the Natcher Auditorium of the National Institutes of Health (NIH).

10 May 2010

Kent State University receives four-year, $2.7M grant to study cognitive status of heart failure patients

The National Institutes of Health has awarded a $2.7-million grant to Kent State University for a collaborative research project with Case Western Reserve University School of Nursing, Summa Health System in Akron and University Hospitals Case Medical Center in Cleveland to study cognitive impairment in heart failure patients.

7 May 2010

Spousal caregivers frequently show memory deficits: Study

Husbands or wives who care for spouses with dementia are six times more likely to develop the memory-impairing condition than those whose spouses don't have it, according to results of a 12-year study led by Johns Hopkins, Utah State University, and Duke University.

7 May 2010

NPWH launches ETIQ campaign to improve access to information about menopause, estrogen therapy

The National Association of Nurse Practitioners in Women's Health announced the launch of Estrogen Therapy I.Q. a campaign devoted to improving access to credible information about menopause and advances in estrogen therapy.

7 May 2010

Closer to understanding age-related memory loss and drug to boost memory

The world's scientific community may be one step closer to understanding age-related memory loss, and to developing a drug that might help boost memory. In an editorial published May 7 in Science, J. David Sweatt, Ph.D., chair of the University of Alabama at Birmingham (UAB) Department of Neurobiology, says that drugs known as histone deacetylase inhibitors are showing great promise in stopping memory loss - and even in boosting the formation of memory in animal models.

7 May 2010

Gene patenting policies affect patient access to testing for disease-causing genes: Study

Policies allowing genes to be patented can make it more difficult for patients to access testing for important disease-causing gene mutations, according to a series of papers in a special online supplement published by Genetics in Medicine, the official peer-reviewed journal of The American College of Medical Genetics.

7 May 2010

Two-day symposium on molecular neuroimaging

Today, SNM's Molecular Imaging Center of Excellence kicked off a two-day symposium bringing together individuals from multiple scientific disciplines-including chemistry, engineering, physics, molecular biology, neurosciences and imaging sciences-to promote the emerging field of molecular neuroimaging.

7 May 2010